NCT03267498View on ClinicalTrials.gov

Nivolumab + Chemoradiation in Stage II-IVB Nasopharyngeal Carcinoma (NPC)

PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

February 14, 2018

Primary Completion Date

October 31, 2024

Study Completion Date

October 31, 2024

Conditions
Nasopharyngeal Carcinoma
Interventions
DRUG

Nivolumab

Dosage 240mg of Nivolumab will be given intravenously over 60 minutes, every 14 days.

DRUG

Cisplatin

Dosage 40 mg/m2 of cisplatin will be given intravenously over 30-60 minutes, every 7 days.

RADIATION

Radiation Therapy

2.12 Gy/fraction x 33 fractions of radiation therapy will be given, daily Monday - Friday

Trial Locations (2)

94143

University of California, San Francisco, San Francisco

119074

National University Hospital Singapore, Singapore

Sponsors

Collaborators (1)

Bristol-Myers Squibb
All Listed Sponsors
collaborator

National University of Singapore

OTHER

collaborator

Bristol-Myers Squibb

INDUSTRY

lead

Sue Yom

OTHER

NCT03267498 - Nivolumab + Chemoradiation in Stage II-IVB Nasopharyngeal Carcinoma (NPC) | Biotech Hunter | Biotech Hunter